Arbutus Biopharma Falls Most Since 2020, Loses Patent Appeal
Arbutus Biopharmashares sink as much as 22%, the most intraday since 2020, after the European Patent Office appeals board revoked one of its patents, which is likely to affect its case against Moderna in Switzerland and one Unified Patent Court case.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.